Submit Deal

CELGENE CORPORATION

Summary

Celgene is a global biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases.

Deals Overview

Total Deals7

Valued Deals6

Total Value£ 99.06 B

Avg. Deal Size£ 16.51 B

Market Context

Subsidiaries

OTEZLA

1 transaction

Senior Management

Peter N. Kellogg
Chief Corporate Strategy Officer & Executive Vice President
Jonathan Biller
General Counsel

Sort

07 Jan 2018|United States|Biotechnology

Target: IMPACT BIOMEDICINES

Bidder: CELGENE CORPORATION

2 Service Providers

1 Target | 1 Bidder

10 Dealmakers

2 Target | 8 Bidder

£ 811 M

Value

22 Jan 2018|United States|Biotechnology

Target: JUNO THERAPEUTICS INC

Bidder: CELGENE CORPORATION

9 Service Providers

4 Target | 5 Bidder

60 Dealmakers

22 Target | 38 Bidder

£ 5.86 B

Value

14 Jul 2015|United States|Biotechnology

Target: RECEPTOS INC.

Bidder: CELGENE CORPORATION

2 Service Providers

2 Target

4 Dealmakers

4 Target

£ 4.64 B

Value

03 Jan 2019|United States|Biotechnology

Target: CELGENE CORPORATION

Bidder: BRISTOL MYERS SQUIBB COMPANY

22 Service Providers

10 Target | 12 Bidder

83 Dealmakers

40 Target | 43 Bidder

£ 70.66 B

Value

26 Aug 2019|United States|Pharmaceuticals

Target: OTEZLA

Bidder: AMGEN INC

13 Service Providers

5 Bidder | 8 Vendor

46 Dealmakers

18 Bidder | 28 Vendor

£ 10.90 B

Value

25 Sep 2019|United States|Biotechnology

Target: ATXCO INC

Bidder: BLADE THERAPEUTICS

5 Service Providers

1 Target | 2 Bidder | 2 Vendor

7 Dealmakers

1 Target | 4 Bidder | 2 Vendor

n/a

Value

21 Sep 2020|United States|Medical Services

Target: GRAIL

Bidder: ILLUMINA INC

29 Service Providers

7 Target | 7 Bidder | 15 Vendor

107 Dealmakers

42 Target | 41 Bidder | 24 Vendor

£ 6.19 B

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy